UA46739C2

UA46739C2 - Спосіб виробництва медикаменту для профілактики або лікування людей або тварин, які уражені ендотоксемією, фармацевтична композиція, вільна від білків та пептидів (варіанти)

Спосіб виробництва медикаменту для профілактики або лікування людей або тварин, які уражені ендотоксемією, фармацевтична композиція, вільна від білків та пептидів (варіанти) Download PDF

Info

Publication number: UA46739C2
Authority: UA; Ukraine
Prior art keywords: fact; pharmaceutical composition; composition according; phospholipid; lipid
Prior art date: 1994-08-10

Application number

UA97020536A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Inventor

Деніел М. ЛІВАЙН

Томас С. Паркер

Альберт Л. РУБІН

Брюс Р. Гордон

Стюарт Д. САЛ

Original Assignee

Сепсік'Юр, Л.Л.К.

Priority date

1994-08-10

Filing date

1995-08-10

Publication date

2002-06-17

1994-08-10 Priority claimed from US08/288,568 external-priority patent/US5506218A/en

1995-06-07 Priority claimed from US08/487,459 external-priority patent/US5674855A/en

1995-08-10 Application filed by Сепсік'Юр, Л.Л.К. filed Critical Сепсік'Юр, Л.Л.К.

2002-06-17 Publication of UA46739C2 publication Critical patent/UA46739C2/uk

Links

239000000203 mixture Substances 0.000 title claims abstract description 48
238000011282 treatment Methods 0.000 title claims abstract description 13
238000000034 method Methods 0.000 title claims description 18
230000002265 prevention Effects 0.000 title claims description 11
241001465754 Metazoa Species 0.000 title claims description 10
238000004519 manufacturing process Methods 0.000 title claims description 6
208000037487 Endotoxemia Diseases 0.000 title 1
150000003904 phospholipids Chemical class 0.000 claims abstract description 70
150000002632 lipids Chemical class 0.000 claims abstract description 64
230000007935 neutral effect Effects 0.000 claims abstract description 44
239000003613 bile acid Substances 0.000 claims abstract description 26
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 24
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 24
102000004169 proteins and genes Human genes 0.000 claims abstract description 16
108090000623 proteins and genes Proteins 0.000 claims abstract description 16
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 35
239000000839 emulsion Substances 0.000 claims description 28
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 28
150000003839 salts Chemical class 0.000 claims description 23
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 15
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 13
229940099352 cholate Drugs 0.000 claims description 11
102000004196 processed proteins & peptides Human genes 0.000 claims description 11
-1 bile acid salt Chemical class 0.000 claims description 7
238000001990 intravenous administration Methods 0.000 claims description 7
150000001840 cholesterol esters Chemical class 0.000 claims description 5
229960003964 deoxycholic acid Drugs 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims description 4
150000003408 sphingolipids Chemical class 0.000 claims description 4
WDFRNBJHDMUMBL-OICFXQLMSA-M sodium;(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-OICFXQLMSA-M 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims 25
RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 claims 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
239000008196 pharmacological composition Substances 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
239000011734 sodium Substances 0.000 claims 1
150000003626 triacylglycerols Chemical class 0.000 abstract description 43
239000002158 endotoxin Substances 0.000 abstract description 21
231100000419 toxicity Toxicity 0.000 abstract description 9
230000001988 toxicity Effects 0.000 abstract description 9
238000011321 prophylaxis Methods 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 68
235000012000 cholesterol Nutrition 0.000 description 33
239000002245 particle Substances 0.000 description 26
108010010234 HDL Lipoproteins Proteins 0.000 description 21
102000015779 HDL Lipoproteins Human genes 0.000 description 21
229920006008 lipopolysaccharide Polymers 0.000 description 20
238000002474 experimental method Methods 0.000 description 17
239000000463 material Substances 0.000 description 15
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
210000002381 plasma Anatomy 0.000 description 12
239000002502 liposome Substances 0.000 description 10
102000004895 Lipoproteins Human genes 0.000 description 9
108090001030 Lipoproteins Proteins 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
235000010469 Glycine max Nutrition 0.000 description 8
238000012360 testing method Methods 0.000 description 8
108010071619 Apolipoproteins Proteins 0.000 description 7
102000007592 Apolipoproteins Human genes 0.000 description 7
102000006410 Apoproteins Human genes 0.000 description 7
108010083590 Apoproteins Proteins 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
108010062497 VLDL Lipoproteins Proteins 0.000 description 6
239000000693 micelle Substances 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
102000007330 LDL Lipoproteins Human genes 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000002253 acid Substances 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
210000003205 muscle Anatomy 0.000 description 5
230000035899 viability Effects 0.000 description 5
208000005374 Poisoning Diseases 0.000 description 4
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 4
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
230000037396 body weight Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
231100000572 poisoning Toxicity 0.000 description 4
230000000607 poisoning effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000002195 soluble material Substances 0.000 description 4
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 4
229940117972 triolein Drugs 0.000 description 4
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
239000004215 Carbon black (E152) Substances 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
229930003427 Vitamin E Natural products 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
235000019416 cholic acid Nutrition 0.000 description 3
239000002812 cholic acid derivative Substances 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000003599 detergent Substances 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
235000013601 eggs Nutrition 0.000 description 3
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
150000002430 hydrocarbons Chemical class 0.000 description 3
230000003993 interaction Effects 0.000 description 3
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
229940031439 squalene Drugs 0.000 description 3
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
235000019165 vitamin E Nutrition 0.000 description 3
229940046009 vitamin E Drugs 0.000 description 3
239000011709 vitamin E Substances 0.000 description 3
230000003313 weakening effect Effects 0.000 description 3
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
102000005666 Apolipoprotein A-I Human genes 0.000 description 2
108010059886 Apolipoprotein A-I Proteins 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
239000004380 Cholic acid Substances 0.000 description 2
206010053172 Fatal outcomes Diseases 0.000 description 2
101000941029 Homo sapiens Endoplasmic reticulum junction formation protein lunapark Proteins 0.000 description 2
101000991410 Homo sapiens Nucleolar and spindle-associated protein 1 Proteins 0.000 description 2
102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 2
108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960002471 cholic acid Drugs 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
244000144993 groups of animals Species 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000010410 layer Substances 0.000 description 2
231100000636 lethal dose Toxicity 0.000 description 2
239000002960 lipid emulsion Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
108010028522 peptide 18A Proteins 0.000 description 2
230000001698 pyrogenic effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
229960003080 taurine Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DKPMWHFRUGMUKF-UHFFFAOYSA-N (3alpha,5alpha,6alpha,7alpha)-3,6,7-Trihydroxycholan-24-oic acid Natural products OC1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DKPMWHFRUGMUKF-UHFFFAOYSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
JOYGXTIHTHBSOA-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-thiophen-2-ylprop-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C=CC1=CC=CS1 JOYGXTIHTHBSOA-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
102000018655 Apolipoproteins C Human genes 0.000 description 1
108010027070 Apolipoproteins C Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
108010004103 Chylomicrons Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
102100025889 Lon protease homolog 2, peroxisomal Human genes 0.000 description 1
101710167388 Lon protease homolog, mitochondrial Proteins 0.000 description 1
102100030991 Nucleolar and spindle-associated protein 1 Human genes 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
241000219995 Wisteria Species 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000003855 balanced salt solution Substances 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004159 blood analysis Methods 0.000 description 1
238000007664 blowing Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
150000001842 cholic acids Chemical class 0.000 description 1
238000004590 computer program Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
235000021149 fatty food Nutrition 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000005661 hydrophobic surface Effects 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
238000002156 mixing Methods 0.000 description 1
235000000010 nanu Nutrition 0.000 description 1
244000082862 nanu Species 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000016236 parenteral nutrition Nutrition 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
229950005143 sitosterol Drugs 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
BHQCQFFYRZLCQQ-UTLSPDKDSA-N ursocholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UTLSPDKDSA-N 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
238000005303 weighing Methods 0.000 description 1